Publications & Funding

Co-opting signalling molecules enables logic-gated control of CAR T cells

Tousley AM, Rotiroti MC, Labanieh L, Rysavy LW, Kim WJ, Lareau C, Sotillo E, Weber EW, Rietberg SP, Dalton GN, Yin Y, Klysz D, Xu P, de la Serna EL, Dunn AR, Satpathy AT, Mackall CL, Majzner RG

Nature

March 2023

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

Christian L Flugel, Robbie G Majzner, Giedre Krenciute, Gianpietro Dotti, Stanley R Riddell, Dimitrios L Wagner, Mohamed Abou-El-Enein

Nature Reviews Clinical Oncology

November 2022

Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1

Mabe NW, Huang M, Dalton GN, Alexe G, Schaefer DA, Geraghty AC, Robichaud AL, Conway AS, Khalid D, Mader MM, Belk JA, Ross KN, Sheffer M, Linde MH, Ly N, Yao W, Rotiroti MC, Smith BAH, Wernig M, Bertozzi CR, Monje M, Mitsiades CS, Majeti R, Satpathy AT, Stegmaier K, Majzner RG.

Nature Cancer

August 2022

Immunotherapy of Neuroblastoma: Facts and Hopes

John Anderson, Robbie G Majzner, Paul M Sondel

Clinical Cancer Research

August 2022

Enhanced safety and efficacy of protease-regulated CAR-T cell receptors

Louai Labanieh, Robbie G Majzner, Dorota Klysz, Elena Sotillo, Chris J Fisher, José G Vilches-Moure, Kaithlen Zen B Pacheco, Meena Malipatlolla, Peng Xu, Jessica H Hui, Tara Murty, Johanna Theruvath, Nishant Mehta, Sean A Yamada-Hunter, Evan W Weber, Sabine Heitzeneder, Kevin R Parker, Ansuman T Satpathy, Howard Y Chang, Michael Z Lin, Jennifer R Cochran, Crystal L Mackall

Cell

May 2022

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

Theruvath J, Menard M, Smith BAH, Linde MH, Coles GL, Dalton GN, Wu W, Kiru L, Delaidelli A, Sotillo E, Silberstein JL, Geraghty AC, Banuelos A, Radosevich MT, Dhingra S, Heitzeneder S, Tousley A, Lattin J, Xu P, Huang J, Nasholm N, He A, Kuo TC, Sangalang ERB, Pons J, Barkal A, Brewer RE, Marjon KD, Vilches-Moure JG, Marshall PL, Fernandes R, Monje M, Cochran JR, Sorensen PH, Daldrup-Link HE, Weissman IL, Sage J, Majeti R, Bertozzi CR, Weiss WA, Mackall CL, Majzner RG.

Nature Medicine

February 2022

In vivo imaging of nanoparticle-labeled CAR T cells

Louise Kiru, Aimen Zlitni, Aidan Michael Tousley, Guillermo Nicolás Dalton, Wei Wu, Famyrah Lafortune, Anna Liu, Kristen May Cunanan, Hossein Nejadnik, Todd Sulchek, Michael Eugene Moseley, Robbie G Majzner, Heike Elisabeth Daldrup-Link

PNAS

February 2022

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity

Sabine Heitzeneder, Kristopher R Bosse, Zhongyu Zhu, Doncho Zhelev, Robbie G Majzner, Molly T Radosevich, Shaurya Dhingra, Elena Sotillo, Samantha Buongervino, Guillem Pascual-Pasto, Emily Garrigan, Peng Xu, Jing Huang, Benjamin Salzer, Alberto Delaidelli, Swetha Raman, Hong Cui, Benjamin Martinez, Scott J Bornheimer, Bita Sahaf, Anya Alag, Irfete S Fetahu, Martin Hasselblatt, Kevin R Parker, Hima Anbunathan, Jennifer Hwang, Min Huang, Kathleen Sakamoto, Norman J Lacayo, Dorota D Klysz, Johanna Theruvath, José G Vilches-Moure, Ansuman T Satpathy, Howard Y Chang, Manfred Lehner, Sabine Taschner-Mandl, Jean-Phillipe Julien, Poul H Sorensen, Dimiter S Dimitrov, John M Maris, Crystal L Mackall

Cancer Cell

January 2022

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Jay Y Spiegel, Shabnum Patel, Lori Muffly, Nasheed M Hossain, Jean Oak, John H Baird, Matthew J Frank, Parveen Shiraz, Bita Sahaf, Juliana Craig, Maria Iglesias, Sheren Younes, Yasodha Natkunam, Michael G Ozawa, Eric Yang, John Tamaresis, Harshini Chinnasamy, Zach Ehlinger, Warren Reynolds, Rachel Lynn, Maria Caterina Rotiroti, Nikolaos Gkitsas, Sally Arai, Laura Johnston, Robert Lowsky, Robbie G Majzner, Everett Meyer, Robert S Negrin, Andrew R Rezvani, Surbhi Sidana, Judith Shizuru, Wen-Kai Weng, Chelsea Mullins, Allison Jacob, Ilan Kirsch, Magali Bazzano, Jing Zhou, Sean Mackay, Scott J Bornheimer, Liora Schultz, Sneha Ramakrishna, Kara L Davis, Katherine A Kong, Nirali N Shah, Haiying Qin, Terry Fry, Steven Feldman, Crystal L Mackall, David B Miklos

Nature Medicine

August 2021

Funding

We are currently funded by:

  • The National Institute of Health/Office of the Director (DP2, New Innovator Award)
  • The National Institute of Health/National Cancer Institute (U01, P01)
  • Cancer Grand Challenges (co-funded by CRUK, Mark Foundation, and the National Cancer Institute)
  • The Department of Defense
  • The Parker Institute for Cancer Immunotherapy
  • Cancer Research Institute
  • Doris Duke Charitable Foundation
  • Alex’s Lemonade Stand Foundation
  • The V Foundation
  • Solving Kids’ Cancer
  • ChadTough Foundation

Previous funding has included:

  • AACR
  • St. Baldrick’s Foundation
funding-logo
funding-logo
funding-logo
funding-logo
funding-logo
funding-logo
funding-logo
funding-logo
funding-logo
funding-logo
funding-logo
funding-logo
funding-logo